SCHEMBL5200239

SCHEMBL5200239

CC(C)CNS(=O)(=O)c1cccs1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.66
CYP2C19 P33261 2/20 0.66
CYP2D6 P10635 1/20 0.66
TP53 P04637 1/20 0.52
NPC1 O15118 2/20 0.51
TSHR P16473 2/20 0.51
HPGD P15428 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
ALDH1A1 P00352 3/20 0.50
RAB9A P51151 1/20 0.50
ATM Q13315 1/20 0.50
KDM4E B2RXH2 1/20 0.49
POLB P06746 1/20 0.48
RECQL P46063 1/20 0.48
ESR2 Q92731 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655445 0.80 CYP2D6 (0.72) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL24812582 0.77 CYP2D6 (0.62) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL5512457 0.77 CYP2D6 (0.68) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL5652601 0.77 CYP2D6 (0.79) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL7915450 0.77 CYP2D6 (0.56) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL28588864 0.77 CYP2D6 (0.72) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL15018169 0.76 CYP2D6 (0.66) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL26242973 0.76 CYP2D6 (0.66) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL15009831 0.76 CYP2C9 (0.66) CYP2C9CYP2C19CYP2D6TP53NPC1
SCHEMBL9289455 0.75 CYP2D6 (0.55) CYP2C9CYP2C19CYP2D6NPC1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2791121-B1 BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN INC (US) 2016-08-03 EP disclosed
US-8524745-B2 Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators ALLERGAN, INC. (US) 2013-09-03 US disclosed
US-20130150413-A1 BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-06-13 US disclosed
US-7449447-B2 Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2008-11-11 US disclosed
EP-1869023-A1 NEW TRICYCLIC ANGIOTENSIN II AGONISTS Vicore Pharma AB (SE) 2007-12-26 EP disclosed
EP-1869009-A1 NEW BICYCLIC ANGIOTENSIN II AGONISTS Vicore Pharma AB (SE) 2007-12-26 EP disclosed
US-20070203183-A1 Diaryl piperidines as CB1 modulators SCHERING CORPORATION 2007-08-30 US disclosed
WO-2006109048-A1 NEW TRICYCLIC ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2006-10-19 WO disclosed
WO-2006109058-A1 NEW BICYCLIC ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203183-A1 Diaryl piperidines as CB1 modulators CNR1, CNR2, GPR119 CYP2C9 1090/4885CYP2C19 902/4885CYP2D6 1103/4885
US-20130150413-A1 BENZISOTHIAZOL-3(1H)-ONE-5-SULFONYL DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS CCR5, CCR2, CX3CR1 CYP2C9 3030/4885CYP2C19 3083/4885CYP2D6 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.